Treatment for HIV infection.
Monitor viral load (plasma HIV-RNA) prior to initiation or modification of treatment.
Monitor CD4 cell counts prior to initiation or with modification of ARV treatment and every 3 -6 months; thereafter during at least the first 2 years of treatment.
Monitor hepatitis B screening at baseline and with modification of ARV treatment.
Perform hepatitis C antibody testing prior to initiation or modification of ARV treatment.
Monitor ALT, AST, and total bilirubin at baseline and with modification of ARV treatment.
Common
Serious
Multiple drug-drug interactions
Antimicrobial class: Antiretroviral agent, HIV-1 protease inhibitor
Pregnancy category: B
Average serum half life: 6.5-7.9 hours (unboosted), 8.6-18.1hours (boosted with ritonavir)
Urine penetration: Therapeutic
CSF penetration: Therapeutic
Precautions: Use caution in patients with mild to moderate hepatic impairment (Child-Pugh class B); use unboosted atazanavir only; dose adjustments recommended for treatment-naive patients.
Use caution in patients with preexisting conduction system disease; monitoring recommended.
Consider alternative treatment options in high risk renal patients; monitoring recommended and discontinuation may be required.
Use is not recommended in HIV treatment-experienced patients with end-stage renal disease managed by hemodialysis.
Discontinue if severe rash develops.
Initiation or dose adjustment of insulin or oral hypoglycemic agent may be required.